| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 128 | 2023 | 186 | 26.040 |
Why?
|
| Fragile X Mental Retardation Protein | 68 | 2023 | 113 | 7.090 |
Why?
|
| Autism Spectrum Disorder | 18 | 2023 | 63 | 5.310 |
Why?
|
| Niemann-Pick Disease, Type C | 16 | 2023 | 21 | 5.010 |
Why?
|
| Tremor | 28 | 2023 | 101 | 3.750 |
Why?
|
| Ataxia | 26 | 2023 | 75 | 3.630 |
Why?
|
| Child | 80 | 2023 | 1131 | 3.420 |
Why?
|
| Neurodevelopmental Disorders | 8 | 2022 | 18 | 3.220 |
Why?
|
| Mutation | 50 | 2021 | 307 | 3.120 |
Why?
|
| Humans | 251 | 2023 | 24703 | 3.090 |
Why?
|
| Adolescent | 70 | 2023 | 1992 | 2.870 |
Why?
|
| Female | 161 | 2023 | 14048 | 2.520 |
Why?
|
| Intellectual Disability | 13 | 2023 | 43 | 2.500 |
Why?
|
| Child, Preschool | 57 | 2023 | 567 | 2.450 |
Why?
|
| Male | 157 | 2023 | 13669 | 2.410 |
Why?
|
| Sleep Apnea, Central | 19 | 2021 | 29 | 2.360 |
Why?
|
| Heterozygote | 25 | 2022 | 95 | 2.250 |
Why?
|
| Homeodomain Proteins | 28 | 2021 | 56 | 2.110 |
Why?
|
| Transcription Factors | 29 | 2019 | 157 | 2.060 |
Why?
|
| Trinucleotide Repeat Expansion | 21 | 2023 | 43 | 2.000 |
Why?
|
| Adult | 86 | 2023 | 7255 | 1.940 |
Why?
|
| Phenotype | 35 | 2023 | 280 | 1.770 |
Why?
|
| Young Adult | 45 | 2023 | 1847 | 1.710 |
Why?
|
| Hypoventilation | 20 | 2021 | 38 | 1.690 |
Why?
|
| Autistic Disorder | 10 | 2023 | 37 | 1.670 |
Why?
|
| Language | 7 | 2023 | 53 | 1.580 |
Why?
|
| Nerve Tissue Proteins | 23 | 2023 | 151 | 1.540 |
Why?
|
| Sudden Infant Death | 13 | 2013 | 36 | 1.460 |
Why?
|
| Chromosome Disorders | 9 | 2023 | 14 | 1.430 |
Why?
|
| Cognition Disorders | 15 | 2018 | 943 | 1.420 |
Why?
|
| Infant | 38 | 2023 | 482 | 1.380 |
Why?
|
| Indoles | 4 | 2019 | 31 | 1.360 |
Why?
|
| Cyclodextrins | 2 | 2020 | 7 | 1.240 |
Why?
|
| Epilepsy | 9 | 2017 | 68 | 1.230 |
Why?
|
| Language Tests | 6 | 2021 | 22 | 1.230 |
Why?
|
| Cognition | 16 | 2023 | 1237 | 1.160 |
Why?
|
| Alleles | 23 | 2021 | 197 | 1.120 |
Why?
|
| Animals | 42 | 2022 | 3330 | 1.110 |
Why?
|
| Seizures | 8 | 2022 | 68 | 1.110 |
Why?
|
| Attention | 5 | 2022 | 97 | 1.100 |
Why?
|
| Genetic Predisposition to Disease | 20 | 2021 | 358 | 1.090 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 7 | 2019 | 10 | 1.090 |
Why?
|
| Registries | 5 | 2020 | 176 | 1.050 |
Why?
|
| Genetic Testing | 10 | 2016 | 54 | 1.030 |
Why?
|
| Neuropsychological Tests | 22 | 2022 | 1135 | 1.020 |
Why?
|
| Clinical Trials as Topic | 7 | 2021 | 193 | 1.000 |
Why?
|
| Trinucleotide Repeats | 8 | 2021 | 10 | 0.950 |
Why?
|
| Spinal Puncture | 2 | 2023 | 23 | 0.950 |
Why?
|
| Glutamates | 4 | 2023 | 9 | 0.930 |
Why?
|
| Down Syndrome | 6 | 2022 | 10 | 0.880 |
Why?
|
| Autonomic Nervous System Diseases | 11 | 2016 | 24 | 0.880 |
Why?
|
| Executive Function | 7 | 2023 | 102 | 0.850 |
Why?
|
| Vocabulary | 2 | 2023 | 8 | 0.850 |
Why?
|
| Behavioral Symptoms | 2 | 2022 | 12 | 0.840 |
Why?
|
| Angelman Syndrome | 1 | 2023 | 2 | 0.840 |
Why?
|
| Carrier Proteins | 4 | 2020 | 92 | 0.830 |
Why?
|
| Receptors, Metabotropic Glutamate | 7 | 2019 | 13 | 0.820 |
Why?
|
| Genetic Carrier Screening | 8 | 2017 | 9 | 0.810 |
Why?
|
| Middle Aged | 48 | 2022 | 8294 | 0.800 |
Why?
|
| Cannabidiol | 1 | 2022 | 3 | 0.800 |
Why?
|
| Gastrointestinal Diseases | 2 | 2020 | 24 | 0.790 |
Why?
|
| Developmental Disabilities | 8 | 2022 | 24 | 0.780 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 6 | 2023 | 7 | 0.770 |
Why?
|
| Case-Control Studies | 25 | 2021 | 555 | 0.770 |
Why?
|
| Mental Disorders | 5 | 2022 | 139 | 0.750 |
Why?
|
| Treatment Outcome | 19 | 2023 | 3208 | 0.730 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2021 | 1 | 0.720 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2021 | 5 | 0.720 |
Why?
|
| Severity of Illness Index | 9 | 2021 | 814 | 0.720 |
Why?
|
| Parkinsonian Disorders | 4 | 2020 | 205 | 0.710 |
Why?
|
| Hypersensitivity | 2 | 2020 | 37 | 0.710 |
Why?
|
| Pupil | 2 | 2019 | 3 | 0.710 |
Why?
|
| DNA Methylation | 8 | 2022 | 154 | 0.700 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2020 | 1 | 0.700 |
Why?
|
| Neonatal Screening | 4 | 2018 | 6 | 0.690 |
Why?
|
| Neurotransmitter Agents | 3 | 2017 | 15 | 0.690 |
Why?
|
| Food, Formulated | 1 | 2020 | 4 | 0.690 |
Why?
|
| Brain Waves | 1 | 2020 | 5 | 0.690 |
Why?
|
| Infant Formula | 1 | 2020 | 18 | 0.680 |
Why?
|
| Rett Syndrome | 4 | 2023 | 5 | 0.680 |
Why?
|
| Auditory Perception | 1 | 2020 | 33 | 0.670 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2020 | 64 | 0.670 |
Why?
|
| Anesthetics | 1 | 2020 | 23 | 0.660 |
Why?
|
| Genetic Association Studies | 6 | 2022 | 81 | 0.660 |
Why?
|
| Reproducibility of Results | 13 | 2023 | 598 | 0.660 |
Why?
|
| Fixation, Ocular | 2 | 2019 | 3 | 0.650 |
Why?
|
| Toilet Training | 1 | 2019 | 1 | 0.650 |
Why?
|
| Neurons | 12 | 2022 | 326 | 0.650 |
Why?
|
| Language Development Disorders | 1 | 2019 | 4 | 0.650 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 46 | 0.640 |
Why?
|
| Comorbidity | 8 | 2022 | 447 | 0.640 |
Why?
|
| Biomarkers | 12 | 2023 | 520 | 0.630 |
Why?
|
| Behavior | 3 | 2016 | 23 | 0.630 |
Why?
|
| Comprehension | 1 | 2019 | 29 | 0.630 |
Why?
|
| Mice | 26 | 2021 | 1296 | 0.630 |
Why?
|
| Genetic Counseling | 4 | 2016 | 4 | 0.620 |
Why?
|
| RNA-Binding Proteins | 8 | 2005 | 20 | 0.620 |
Why?
|
| Brain | 23 | 2015 | 1539 | 0.620 |
Why?
|
| Genetic Therapy | 5 | 2016 | 84 | 0.610 |
Why?
|
| Aged | 43 | 2023 | 8382 | 0.600 |
Why?
|
| Cyclic AMP | 10 | 1998 | 32 | 0.590 |
Why?
|
| Psychometrics | 9 | 2023 | 197 | 0.580 |
Why?
|
| RNA, Messenger | 12 | 2021 | 294 | 0.570 |
Why?
|
| Double-Blind Method | 9 | 2023 | 367 | 0.570 |
Why?
|
| Gait | 4 | 2020 | 407 | 0.560 |
Why?
|
| Adaptation, Psychological | 3 | 2022 | 163 | 0.540 |
Why?
|
| Intelligence | 3 | 2016 | 16 | 0.540 |
Why?
|
| Polymorphism, Genetic | 11 | 2010 | 51 | 0.520 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2016 | 1 | 0.520 |
Why?
|
| Infant, Newborn | 18 | 2020 | 536 | 0.510 |
Why?
|
| Sex Factors | 7 | 2020 | 443 | 0.500 |
Why?
|
| Disease Progression | 9 | 2021 | 632 | 0.500 |
Why?
|
| Hypothalamic Diseases | 5 | 2015 | 7 | 0.500 |
Why?
|
| Child Behavior Disorders | 3 | 2017 | 20 | 0.490 |
Why?
|
| Baclofen | 2 | 2012 | 3 | 0.490 |
Why?
|
| Disease Management | 1 | 2016 | 88 | 0.490 |
Why?
|
| Chromosome Deletion | 8 | 2023 | 16 | 0.490 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2014 | 286 | 0.490 |
Why?
|
| Imidazoles | 3 | 2021 | 54 | 0.470 |
Why?
|
| Anxiety Disorders | 4 | 2022 | 167 | 0.470 |
Why?
|
| Ketosis | 3 | 2005 | 7 | 0.470 |
Why?
|
| Mice, Knockout | 10 | 2019 | 290 | 0.460 |
Why?
|
| Pilot Projects | 8 | 2021 | 370 | 0.460 |
Why?
|
| Polymerase Chain Reaction | 5 | 2021 | 113 | 0.450 |
Why?
|
| Cholesterol | 1 | 2014 | 58 | 0.450 |
Why?
|
| Health Surveys | 3 | 2012 | 84 | 0.440 |
Why?
|
| Psychotropic Drugs | 5 | 2021 | 26 | 0.430 |
Why?
|
| Aged, 80 and over | 22 | 2023 | 4509 | 0.420 |
Why?
|
| Point Mutation | 5 | 2007 | 24 | 0.410 |
Why?
|
| Mothers | 5 | 2023 | 160 | 0.400 |
Why?
|
| Nervous System | 1 | 2012 | 10 | 0.390 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2021 | 31 | 0.390 |
Why?
|
| DNA Mutational Analysis | 14 | 2017 | 55 | 0.390 |
Why?
|
| Electroencephalography | 6 | 2023 | 79 | 0.390 |
Why?
|
| Mosaicism | 6 | 2021 | 9 | 0.380 |
Why?
|
| Apolipoproteins E | 8 | 2005 | 235 | 0.380 |
Why?
|
| Stress, Psychological | 4 | 2023 | 217 | 0.370 |
Why?
|
| Piperidines | 2 | 2012 | 12 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 22 | 8 | 2023 | 10 | 0.350 |
Why?
|
| Genotype | 18 | 2019 | 332 | 0.350 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 982 | 0.350 |
Why?
|
| Alzheimer Disease | 8 | 2014 | 2020 | 0.340 |
Why?
|
| Neuroblastoma | 9 | 2006 | 18 | 0.340 |
Why?
|
| Gene Deletion | 5 | 2013 | 41 | 0.340 |
Why?
|
| Antipsychotic Agents | 3 | 2019 | 53 | 0.340 |
Why?
|
| Placebos | 3 | 2021 | 60 | 0.340 |
Why?
|
| DNA | 11 | 2013 | 97 | 0.340 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 2 | 2020 | 9 | 0.330 |
Why?
|
| Phosphorylcholine | 2 | 2020 | 5 | 0.320 |
Why?
|
| Bile Acids and Salts | 3 | 2020 | 10 | 0.320 |
Why?
|
| Blood Platelets | 4 | 2001 | 35 | 0.320 |
Why?
|
| Postural Balance | 3 | 2021 | 112 | 0.310 |
Why?
|
| Parkinson Disease | 6 | 2023 | 633 | 0.310 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2018 | 14 | 0.310 |
Why?
|
| Retrospective Studies | 9 | 2020 | 3156 | 0.310 |
Why?
|
| Peptides | 4 | 2016 | 96 | 0.300 |
Why?
|
| Obesity | 4 | 2015 | 280 | 0.300 |
Why?
|
| Genetic Variation | 5 | 2019 | 90 | 0.300 |
Why?
|
| Disease Models, Animal | 7 | 2019 | 560 | 0.300 |
Why?
|
| Primary Ovarian Insufficiency | 3 | 2021 | 8 | 0.300 |
Why?
|
| Lithium Carbonate | 1 | 2008 | 2 | 0.300 |
Why?
|
| Hirschsprung Disease | 5 | 2012 | 10 | 0.290 |
Why?
|
| Autonomic Nervous System | 5 | 2011 | 19 | 0.290 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1042 | 0.290 |
Why?
|
| Abnormalities, Multiple | 4 | 2010 | 13 | 0.280 |
Why?
|
| Cerebellum | 5 | 2018 | 39 | 0.280 |
Why?
|
| Cohort Studies | 8 | 2016 | 1748 | 0.270 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 54 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 250 | 0.270 |
Why?
|
| United States | 11 | 2022 | 1873 | 0.270 |
Why?
|
| Rare Diseases | 3 | 2022 | 10 | 0.270 |
Why?
|
| Risk Factors | 11 | 2021 | 2099 | 0.270 |
Why?
|
| Siblings | 2 | 2016 | 10 | 0.260 |
Why?
|
| Quality of Life | 5 | 2022 | 541 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2018 | 1026 | 0.260 |
Why?
|
| Neuroprotective Agents | 2 | 2023 | 49 | 0.260 |
Why?
|
| Chromosomes, Human, X | 3 | 2007 | 8 | 0.260 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 26 | 0.260 |
Why?
|
| Dioxoles | 1 | 2006 | 5 | 0.260 |
Why?
|
| Receptors, AMPA | 1 | 2006 | 7 | 0.260 |
Why?
|
| Age of Onset | 9 | 2019 | 89 | 0.260 |
Why?
|
| Pedigree | 7 | 2019 | 54 | 0.260 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2006 | 1 | 0.260 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 4 | 0.260 |
Why?
|
| Nicotine | 1 | 2006 | 5 | 0.260 |
Why?
|
| Nootropic Agents | 2 | 2020 | 14 | 0.260 |
Why?
|
| Family Health | 5 | 2010 | 31 | 0.250 |
Why?
|
| Prevalence | 3 | 2020 | 411 | 0.250 |
Why?
|
| DNA Repeat Expansion | 4 | 2016 | 7 | 0.250 |
Why?
|
| Adenylyl Cyclases | 7 | 1996 | 10 | 0.250 |
Why?
|
| Receptors, Serotonin | 8 | 1993 | 12 | 0.250 |
Why?
|
| Feasibility Studies | 5 | 2021 | 196 | 0.250 |
Why?
|
| Hybrid Cells | 8 | 1988 | 8 | 0.240 |
Why?
|
| Parents | 5 | 2023 | 105 | 0.240 |
Why?
|
| Patient Care Team | 2 | 2020 | 105 | 0.240 |
Why?
|
| Child Development | 2 | 2010 | 69 | 0.240 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 807 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 48 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 253 | 0.240 |
Why?
|
| Longitudinal Studies | 8 | 2020 | 1293 | 0.240 |
Why?
|
| Administration, Oral | 3 | 2012 | 97 | 0.240 |
Why?
|
| Membrane Glycoproteins | 3 | 2017 | 60 | 0.240 |
Why?
|
| Ketone Bodies | 1 | 2005 | 3 | 0.240 |
Why?
|
| Growth | 1 | 2005 | 6 | 0.240 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2005 | 5 | 0.240 |
Why?
|
| Serotonin | 8 | 2008 | 23 | 0.230 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2005 | 1 | 0.230 |
Why?
|
| Signal Transduction | 5 | 2021 | 413 | 0.230 |
Why?
|
| Dendritic Spines | 3 | 2013 | 9 | 0.230 |
Why?
|
| Atrophy | 4 | 2017 | 81 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2023 | 1612 | 0.220 |
Why?
|
| Age Factors | 6 | 2021 | 728 | 0.220 |
Why?
|
| Mitochondrial Proteins | 3 | 2013 | 41 | 0.210 |
Why?
|
| Databases, Factual | 3 | 2021 | 315 | 0.210 |
Why?
|
| Twins, Monozygotic | 2 | 2015 | 8 | 0.210 |
Why?
|
| Learning | 4 | 2013 | 67 | 0.210 |
Why?
|
| Forecasting | 3 | 2017 | 88 | 0.210 |
Why?
|
| Computers | 2 | 2021 | 16 | 0.210 |
Why?
|
| Aminopeptidases | 2 | 2020 | 6 | 0.210 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 2 | 2020 | 6 | 0.210 |
Why?
|
| Serine Proteases | 2 | 2020 | 7 | 0.210 |
Why?
|
| Hyperkinesis | 2 | 2013 | 8 | 0.210 |
Why?
|
| Checklist | 2 | 2014 | 31 | 0.200 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2017 | 12 | 0.200 |
Why?
|
| Psychomotor Performance | 3 | 2020 | 178 | 0.200 |
Why?
|
| Huntington Disease | 3 | 2008 | 45 | 0.200 |
Why?
|
| Niemann-Pick Disease, Type A | 1 | 2022 | 1 | 0.200 |
Why?
|
| Gels | 1 | 2022 | 11 | 0.200 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 91 | 0.200 |
Why?
|
| Epilepsy, Generalized | 1 | 2002 | 2 | 0.200 |
Why?
|
| Walking Speed | 2 | 2020 | 36 | 0.200 |
Why?
|
| Epilepsies, Partial | 1 | 2002 | 14 | 0.200 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2023 | 26 | 0.200 |
Why?
|
| Mitral Valve Prolapse | 1 | 2022 | 1 | 0.200 |
Why?
|
| Autophagy | 2 | 2020 | 23 | 0.190 |
Why?
|
| Syndrome | 11 | 2011 | 69 | 0.190 |
Why?
|
| Movement Disorders | 2 | 2016 | 66 | 0.190 |
Why?
|
| Precision Medicine | 1 | 2022 | 20 | 0.190 |
Why?
|
| Transcriptome | 1 | 2022 | 82 | 0.190 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2021 | 8 | 0.190 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2020 | 57 | 0.190 |
Why?
|
| Carnitine | 1 | 2001 | 8 | 0.190 |
Why?
|
| Pandemics | 1 | 2023 | 190 | 0.190 |
Why?
|
| Hallucinations | 3 | 2011 | 42 | 0.190 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2021 | 25 | 0.190 |
Why?
|
| Anticonvulsants | 3 | 2010 | 52 | 0.180 |
Why?
|
| Sleep | 2 | 2023 | 284 | 0.180 |
Why?
|
| Dried Blood Spot Testing | 2 | 2018 | 2 | 0.180 |
Why?
|
| Minocycline | 2 | 2012 | 5 | 0.180 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 2019 | 6 | 0.180 |
Why?
|
| Genes, Homeobox | 1 | 2021 | 4 | 0.180 |
Why?
|
| Hair | 1 | 2021 | 2 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2021 | 10 | 0.180 |
Why?
|
| Gene-Environment Interaction | 1 | 2021 | 17 | 0.180 |
Why?
|
| Brain Chemistry | 5 | 2013 | 40 | 0.180 |
Why?
|
| Ovary | 1 | 2021 | 21 | 0.180 |
Why?
|
| Neural Stem Cells | 1 | 2021 | 12 | 0.180 |
Why?
|
| Hydrocortisone | 1 | 2021 | 34 | 0.180 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 61 | 0.180 |
Why?
|
| Contusions | 1 | 2001 | 3 | 0.180 |
Why?
|
| Interdisciplinary Communication | 3 | 2020 | 17 | 0.180 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 17 | 0.170 |
Why?
|
| Glycine | 1 | 2020 | 6 | 0.170 |
Why?
|
| Accidental Falls | 2 | 2020 | 107 | 0.170 |
Why?
|
| Enzyme Inhibitors | 2 | 2012 | 112 | 0.170 |
Why?
|
| Menopause | 1 | 2021 | 78 | 0.170 |
Why?
|
| Azides | 1 | 2020 | 2 | 0.170 |
Why?
|
| Alkynes | 1 | 2020 | 4 | 0.170 |
Why?
|
| Microglia | 1 | 2021 | 130 | 0.170 |
Why?
|
| Infusions, Intraventricular | 1 | 2020 | 1 | 0.170 |
Why?
|
| Social Behavior | 2 | 2019 | 64 | 0.170 |
Why?
|
| Infusion Pumps | 1 | 2020 | 6 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 244 | 0.160 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.160 |
Why?
|
| Prenatal Diagnosis | 1 | 2000 | 11 | 0.160 |
Why?
|
| Reflex, Pupillary | 1 | 2019 | 1 | 0.160 |
Why?
|
| Facial Expression | 1 | 2019 | 8 | 0.160 |
Why?
|
| Irritable Mood | 1 | 2019 | 3 | 0.160 |
Why?
|
| Self-Injurious Behavior | 1 | 2019 | 2 | 0.160 |
Why?
|
| Early Diagnosis | 3 | 2017 | 54 | 0.160 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 174 | 0.160 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2014 | 16 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 98 | 0.160 |
Why?
|
| Personality Assessment | 2 | 2012 | 33 | 0.160 |
Why?
|
| Psychomotor Agitation | 1 | 2019 | 12 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 314 | 0.160 |
Why?
|
| Anxiety | 3 | 2022 | 135 | 0.160 |
Why?
|
| Communication | 1 | 2020 | 96 | 0.160 |
Why?
|
| Aggression | 1 | 2019 | 26 | 0.160 |
Why?
|
| Memory, Short-Term | 5 | 2023 | 87 | 0.160 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2019 | 1 | 0.160 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2007 | 11 | 0.160 |
Why?
|
| Biomechanical Phenomena | 3 | 2016 | 630 | 0.160 |
Why?
|
| Speech | 1 | 2019 | 21 | 0.160 |
Why?
|
| Exome | 2 | 2017 | 7 | 0.160 |
Why?
|
| Emotions | 1 | 2019 | 72 | 0.160 |
Why?
|
| Preventive Health Services | 1 | 2019 | 13 | 0.160 |
Why?
|
| Chromatography, Liquid | 3 | 2020 | 21 | 0.150 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 254 | 0.150 |
Why?
|
| Glutamic Acid | 1 | 2019 | 23 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 1671 | 0.150 |
Why?
|
| Agenesis of Corpus Callosum | 2 | 1999 | 2 | 0.150 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 10 | 0.150 |
Why?
|
| X Chromosome | 2 | 1999 | 9 | 0.150 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2018 | 132 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 256 | 0.150 |
Why?
|
| Basal Ganglia | 1 | 2018 | 14 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 140 | 0.150 |
Why?
|
| Cholecystokinin | 2 | 2011 | 5 | 0.150 |
Why?
|
| White Matter | 1 | 2020 | 131 | 0.150 |
Why?
|
| Walking | 1 | 2020 | 244 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 101 | 0.140 |
Why?
|
| Central Nervous System Stimulants | 2 | 2012 | 39 | 0.140 |
Why?
|
| Dopamine | 2 | 2012 | 82 | 0.140 |
Why?
|
| Memory Disorders | 3 | 2016 | 152 | 0.140 |
Why?
|
| Infusions, Spinal | 1 | 2018 | 5 | 0.140 |
Why?
|
| Health Behavior | 1 | 2019 | 154 | 0.140 |
Why?
|
| Cell Line | 11 | 2013 | 244 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 26 | 0.140 |
Why?
|
| Acyltransferases | 1 | 2017 | 3 | 0.140 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 17 | 0.140 |
Why?
|
| Mutation, Missense | 4 | 2019 | 22 | 0.140 |
Why?
|
| Fibroblasts | 3 | 2017 | 53 | 0.140 |
Why?
|
| Pyridines | 1 | 2017 | 26 | 0.140 |
Why?
|
| Disabled Persons | 1 | 2019 | 107 | 0.140 |
Why?
|
| Applied Behavior Analysis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 7 | 0.140 |
Why?
|
| DNA, Mitochondrial | 2 | 2011 | 7 | 0.140 |
Why?
|
| Databases as Topic | 1 | 2017 | 13 | 0.140 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 38 | 0.140 |
Why?
|
| Memory | 2 | 2013 | 281 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 42 | 0.130 |
Why?
|
| Eye Movements | 2 | 2019 | 10 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 13 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 278 | 0.130 |
Why?
|
| Posture | 1 | 2016 | 59 | 0.130 |
Why?
|
| Exons | 5 | 2011 | 29 | 0.130 |
Why?
|
| Sinus Arrest, Cardiac | 1 | 2016 | 1 | 0.120 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 7 | 0.120 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2015 | 1 | 0.120 |
Why?
|
| Orexin Receptors | 1 | 2015 | 1 | 0.120 |
Why?
|
| Orexins | 1 | 2015 | 3 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2020 | 18 | 0.120 |
Why?
|
| Ganglioneuroblastoma | 1 | 2015 | 1 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 68 | 0.120 |
Why?
|
| Ganglioneuroma | 1 | 2015 | 2 | 0.120 |
Why?
|
| Diseases in Twins | 2 | 2015 | 9 | 0.120 |
Why?
|
| Cells, Cultured | 5 | 2012 | 492 | 0.120 |
Why?
|
| Cricetinae | 10 | 1996 | 32 | 0.120 |
Why?
|
| Educational Status | 3 | 2013 | 278 | 0.120 |
Why?
|
| Leukoencephalopathies | 1 | 2015 | 10 | 0.120 |
Why?
|
| Lithium Compounds | 2 | 2012 | 3 | 0.120 |
Why?
|
| Motor Activity | 3 | 2020 | 308 | 0.120 |
Why?
|
| Gangliosides | 2 | 1985 | 6 | 0.120 |
Why?
|
| Nuclear Proteins | 4 | 2008 | 84 | 0.120 |
Why?
|
| Haplotypes | 2 | 2006 | 54 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 151 | 0.120 |
Why?
|
| Mitochondrial Myopathies | 1 | 1994 | 1 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 78 | 0.110 |
Why?
|
| Nervous System Malformations | 1 | 2014 | 3 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2016 | 252 | 0.110 |
Why?
|
| Gemfibrozil | 1 | 2015 | 34 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2015 | 87 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2015 | 95 | 0.110 |
Why?
|
| Space Perception | 3 | 2009 | 22 | 0.110 |
Why?
|
| Antidepressive Agents | 2 | 2019 | 87 | 0.110 |
Why?
|
| Gene Frequency | 7 | 2011 | 55 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2014 | 49 | 0.110 |
Why?
|
| Protein Biosynthesis | 3 | 2021 | 14 | 0.110 |
Why?
|
| DiGeorge Syndrome | 1 | 1994 | 1 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1994 | 6 | 0.110 |
Why?
|
| Multigene Family | 1 | 1994 | 9 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 1994 | 14 | 0.110 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2013 | 1 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2012 | 45 | 0.110 |
Why?
|
| Physicians | 2 | 2016 | 103 | 0.110 |
Why?
|
| PPAR alpha | 1 | 2015 | 62 | 0.110 |
Why?
|
| Face | 1 | 1994 | 21 | 0.110 |
Why?
|
| Cerebral Cortex | 2 | 2008 | 146 | 0.110 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 18 | 0.110 |
Why?
|
| Education | 1 | 2013 | 36 | 0.100 |
Why?
|
| Receptors, Dopamine | 3 | 2001 | 8 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 1994 | 21 | 0.100 |
Why?
|
| Astrocytes | 1 | 2015 | 138 | 0.100 |
Why?
|
| Myotonic Dystrophy | 1 | 2013 | 1 | 0.100 |
Why?
|
| Language Disorders | 1 | 2013 | 6 | 0.100 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 2013 | 1 | 0.100 |
Why?
|
| Iron | 1 | 2013 | 14 | 0.100 |
Why?
|
| Logistic Models | 3 | 2019 | 365 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2013 | 2 | 0.100 |
Why?
|
| Interneurons | 1 | 2013 | 4 | 0.100 |
Why?
|
| Iron Overload | 1 | 2012 | 2 | 0.100 |
Why?
|
| Membrane Transport Proteins | 2 | 2003 | 53 | 0.100 |
Why?
|
| Nerve Net | 1 | 2013 | 38 | 0.100 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 2011 | 4 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2012 | 30 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Germ Cells | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cutis Laxa | 1 | 2012 | 1 | 0.100 |
Why?
|
| Proton-Translocating ATPases | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 53 | 0.100 |
Why?
|
| Lymphocytes | 3 | 2023 | 53 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 19 | 0.100 |
Why?
|
| Reference Values | 3 | 2021 | 174 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 2 | 2011 | 3 | 0.100 |
Why?
|
| Receptors, GABA | 1 | 2012 | 4 | 0.090 |
Why?
|
| Indans | 1 | 2012 | 5 | 0.090 |
Why?
|
| Deglutition | 1 | 2012 | 10 | 0.090 |
Why?
|
| Enkephalin, Leucine | 3 | 1988 | 3 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2012 | 82 | 0.090 |
Why?
|
| Vitamin E | 1 | 2012 | 43 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2011 | 16 | 0.090 |
Why?
|
| Antioxidants | 1 | 2012 | 60 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2011 | 71 | 0.090 |
Why?
|
| Time Factors | 5 | 2020 | 1327 | 0.090 |
Why?
|
| Ion Transport | 1 | 2011 | 22 | 0.090 |
Why?
|
| Corpus Striatum | 2 | 2008 | 65 | 0.090 |
Why?
|
| Zinc | 1 | 2011 | 24 | 0.090 |
Why?
|
| Drosophila Proteins | 1 | 2011 | 7 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2012 | 122 | 0.090 |
Why?
|
| Zebrafish Proteins | 1 | 2011 | 7 | 0.090 |
Why?
|
| Heart Rate | 2 | 2011 | 94 | 0.090 |
Why?
|
| Cricetulus | 7 | 1986 | 10 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 6 | 0.090 |
Why?
|
| Melatonin | 1 | 2012 | 90 | 0.090 |
Why?
|
| Embryo, Mammalian | 3 | 2004 | 23 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 33 | 0.090 |
Why?
|
| Carrier State | 1 | 2010 | 59 | 0.080 |
Why?
|
| Sympathetic Nervous System | 2 | 2007 | 12 | 0.080 |
Why?
|
| Mitochondria | 1 | 2010 | 56 | 0.080 |
Why?
|
| Gene Transfer Techniques | 2 | 2008 | 29 | 0.080 |
Why?
|
| Self Report | 2 | 2023 | 199 | 0.080 |
Why?
|
| Introns | 2 | 2007 | 16 | 0.080 |
Why?
|
| Genetic Markers | 3 | 2005 | 33 | 0.080 |
Why?
|
| Reaction Time | 4 | 2015 | 89 | 0.080 |
Why?
|
| Amyloid beta-Peptides | 1 | 2011 | 305 | 0.080 |
Why?
|
| Maze Learning | 1 | 2009 | 16 | 0.080 |
Why?
|
| Sensory Gating | 1 | 2009 | 3 | 0.080 |
Why?
|
| Reflex, Startle | 1 | 2009 | 4 | 0.080 |
Why?
|
| Base Sequence | 4 | 2012 | 103 | 0.080 |
Why?
|
| Alprostadil | 5 | 1993 | 9 | 0.080 |
Why?
|
| Neural Inhibition | 1 | 2009 | 7 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 32 | 0.080 |
Why?
|
| Early Medical Intervention | 2 | 2020 | 12 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 362 | 0.080 |
Why?
|
| Lysosomes | 2 | 2021 | 23 | 0.080 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2008 | 1 | 0.080 |
Why?
|
| Neurturin | 1 | 2008 | 22 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2008 | 12 | 0.070 |
Why?
|
| Primary Cell Culture | 2 | 2021 | 25 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2008 | 49 | 0.070 |
Why?
|
| Health Status | 3 | 2019 | 195 | 0.070 |
Why?
|
| Respiration, Artificial | 3 | 2016 | 101 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 50 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 1988 | 25 | 0.070 |
Why?
|
| Thyrotropin | 1 | 2008 | 49 | 0.070 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.070 |
Why?
|
| Death, Sudden | 1 | 2008 | 7 | 0.070 |
Why?
|
| Synapses | 1 | 2008 | 33 | 0.070 |
Why?
|
| Apolipoprotein E4 | 6 | 2005 | 250 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2015 | 240 | 0.070 |
Why?
|
| Caregivers | 2 | 2022 | 185 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2007 | 14 | 0.070 |
Why?
|
| Genetic Linkage | 2 | 1999 | 33 | 0.070 |
Why?
|
| Genome, Human | 1 | 2007 | 43 | 0.070 |
Why?
|
| Long QT Syndrome | 1 | 2007 | 5 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2012 | 140 | 0.070 |
Why?
|
| Drosophila melanogaster | 2 | 2021 | 13 | 0.070 |
Why?
|
| Research | 2 | 2017 | 36 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 437 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 2006 | 7 | 0.070 |
Why?
|
| Long-Term Potentiation | 1 | 2006 | 13 | 0.070 |
Why?
|
| Cerebellar Ataxia | 1 | 2006 | 4 | 0.070 |
Why?
|
| Central Nervous System Agents | 1 | 2006 | 7 | 0.070 |
Why?
|
| Brain Mapping | 2 | 2005 | 145 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 23 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2009 | 315 | 0.060 |
Why?
|
| Frameshift Mutation | 1 | 2006 | 3 | 0.060 |
Why?
|
| Penetrance | 1 | 2006 | 2 | 0.060 |
Why?
|
| Dermatoglyphics | 1 | 2006 | 2 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2006 | 3 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 4 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2006 | 5 | 0.060 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factors | 1 | 2006 | 3 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2006 | 48 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2007 | 173 | 0.060 |
Why?
|
| Facies | 1 | 2005 | 2 | 0.060 |
Why?
|
| Visual Perception | 2 | 2008 | 28 | 0.060 |
Why?
|
| Hippocampus | 3 | 2019 | 262 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2021 | 532 | 0.060 |
Why?
|
| Gait Ataxia | 1 | 2005 | 5 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 1998 | 124 | 0.060 |
Why?
|
| Mass Screening | 1 | 2007 | 165 | 0.060 |
Why?
|
| Amyloid | 1 | 2005 | 53 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 27 | 0.060 |
Why?
|
| Nutritional Requirements | 1 | 2005 | 16 | 0.060 |
Why?
|
| Body Height | 1 | 2005 | 35 | 0.060 |
Why?
|
| Contractile Proteins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2005 | 9 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 24 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2005 | 15 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 398 | 0.060 |
Why?
|
| Body Weight | 1 | 2005 | 128 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Psychopharmacology | 1 | 2004 | 2 | 0.050 |
Why?
|
| Neurologic Examination | 3 | 2012 | 97 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2005 | 143 | 0.050 |
Why?
|
| Guanine | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cytosine | 1 | 2023 | 5 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 4 | 0.050 |
Why?
|
| Huntingtin Protein | 3 | 2008 | 12 | 0.050 |
Why?
|
| Karyotyping | 2 | 1994 | 11 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2023 | 1 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2023 | 10 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 2 | 2014 | 50 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 39 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 18 | 0.050 |
Why?
|
| Amniocentesis | 2 | 2000 | 2 | 0.050 |
Why?
|
| Expressed Emotion | 1 | 2023 | 3 | 0.050 |
Why?
|
| DNA Primers | 3 | 2012 | 49 | 0.050 |
Why?
|
| California | 2 | 2018 | 31 | 0.050 |
Why?
|
| Platelet Count | 2 | 2001 | 12 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2003 | 52 | 0.050 |
Why?
|
| Epilepsy, Rolandic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Socialization | 1 | 2022 | 8 | 0.050 |
Why?
|
| Risk | 3 | 2013 | 199 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 19 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2022 | 3 | 0.050 |
Why?
|
| Metabolomics | 1 | 2022 | 14 | 0.050 |
Why?
|
| Electromyography | 2 | 2013 | 70 | 0.050 |
Why?
|
| Parent-Child Relations | 1 | 2023 | 38 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2017 | 571 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 181 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 18 | 0.050 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 3 | 1993 | 6 | 0.050 |
Why?
|
| Colforsin | 3 | 1993 | 12 | 0.050 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2022 | 8 | 0.050 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 3 | 1988 | 3 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2022 | 29 | 0.050 |
Why?
|
| Snoring | 1 | 2021 | 3 | 0.050 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Artifacts | 1 | 2022 | 27 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2001 | 11 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2001 | 12 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2001 | 38 | 0.050 |
Why?
|
| Incidence | 3 | 2014 | 697 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 132 | 0.050 |
Why?
|
| Genetic Background | 1 | 2021 | 2 | 0.050 |
Why?
|
| Fertility | 1 | 2021 | 12 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 19 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 2 | 0.040 |
Why?
|
| Biological Assay | 1 | 2021 | 5 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 12 | 0.040 |
Why?
|
| Task Performance and Analysis | 2 | 2013 | 46 | 0.040 |
Why?
|
| Morpholines | 1 | 2021 | 13 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2021 | 8 | 0.040 |
Why?
|
| Organoids | 1 | 2021 | 7 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 24 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 21 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 36 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 84 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 93 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 35 | 0.040 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 1 | 2020 | 3 | 0.040 |
Why?
|
| Mental Retardation, X-Linked | 1 | 2020 | 3 | 0.040 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2020 | 3 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 10 | 0.040 |
Why?
|
| Creatine | 1 | 2020 | 6 | 0.040 |
Why?
|
| Reference Standards | 2 | 2013 | 18 | 0.040 |
Why?
|
| Social Communication Disorder | 1 | 2020 | 2 | 0.040 |
Why?
|
| Click Chemistry | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cycloaddition Reaction | 1 | 2020 | 1 | 0.040 |
Why?
|
| Clonidine | 3 | 1985 | 17 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2021 | 129 | 0.040 |
Why?
|
| Piperazines | 1 | 2021 | 75 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2021 | 167 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Behavior Rating Scale | 1 | 2020 | 2 | 0.040 |
Why?
|
| Walk Test | 1 | 2020 | 9 | 0.040 |
Why?
|
| Social Skills | 1 | 2020 | 11 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 262 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 172 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2000 | 8 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 23 | 0.040 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 18 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2000 | 21 | 0.040 |
Why?
|
| Cats | 1 | 2020 | 28 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 42 | 0.040 |
Why?
|
| Risperidone | 1 | 2019 | 4 | 0.040 |
Why?
|
| Genitalia | 1 | 1999 | 1 | 0.040 |
Why?
|
| Pregnancy | 2 | 2017 | 315 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 6 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 7 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 330 | 0.040 |
Why?
|
| Codon, Terminator | 1 | 2019 | 2 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 9 | 0.040 |
Why?
|
| Dental Care | 1 | 2019 | 2 | 0.040 |
Why?
|
| Immunization | 1 | 2019 | 13 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 284 | 0.040 |
Why?
|
| Hexokinase | 1 | 2019 | 1 | 0.040 |
Why?
|
| ras Proteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 24 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 92 | 0.040 |
Why?
|
| Vaccination | 1 | 2019 | 22 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 131 | 0.040 |
Why?
|
| Trisomy | 1 | 1998 | 3 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1998 | 5 | 0.040 |
Why?
|
| Skin | 2 | 2012 | 116 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2019 | 42 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2019 | 106 | 0.040 |
Why?
|
| New York | 1 | 2018 | 11 | 0.040 |
Why?
|
| Michigan | 1 | 2018 | 17 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 6 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 93 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 1998 | 34 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2008 | 129 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 130 | 0.040 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2017 | 2 | 0.040 |
Why?
|
| Muscle Hypotonia | 1 | 2017 | 3 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 674 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2018 | 118 | 0.040 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 2017 | 1 | 0.030 |
Why?
|
| Hydroxycholesterols | 1 | 2017 | 1 | 0.030 |
Why?
|
| Calbindins | 1 | 2017 | 2 | 0.030 |
Why?
|
| Parental Consent | 1 | 2017 | 1 | 0.030 |
Why?
|
| Dependovirus | 2 | 2008 | 39 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2017 | 35 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2017 | 12 | 0.030 |
Why?
|
| Intersectoral Collaboration | 1 | 2017 | 6 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 44 | 0.030 |
Why?
|
| Kinetics | 3 | 1996 | 149 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2008 | 210 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 145 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2011 | 251 | 0.030 |
Why?
|
| Radiography | 2 | 2012 | 611 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 30 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 71 | 0.030 |
Why?
|
| Rats | 3 | 2006 | 609 | 0.030 |
Why?
|
| Breath Holding | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, Opioid, kappa | 1 | 1996 | 2 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1995 | 17 | 0.030 |
Why?
|
| Neuroglia | 1 | 1996 | 47 | 0.030 |
Why?
|
| Motor Skills | 1 | 2016 | 45 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 37 | 0.030 |
Why?
|
| Exercise | 1 | 2019 | 399 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 49 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2015 | 11 | 0.030 |
Why?
|
| Minisatellite Repeats | 2 | 2006 | 7 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 64 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 32 | 0.030 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2015 | 6 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 14 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2015 | 12 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 10 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 708 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2015 | 15 | 0.030 |
Why?
|
| PPAR-beta | 1 | 2015 | 9 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 37 | 0.030 |
Why?
|
| Aging | 1 | 2004 | 1460 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1994 | 3 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1994 | 3 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 110 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1994 | 4 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2011 | 150 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 24 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 21 | 0.030 |
Why?
|
| Georgia | 1 | 2014 | 10 | 0.030 |
Why?
|
| Sandhoff Disease | 1 | 1994 | 1 | 0.030 |
Why?
|
| Motor Neuron Disease | 1 | 1994 | 4 | 0.030 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 1994 | 2 | 0.030 |
Why?
|
| Palate | 1 | 1994 | 4 | 0.030 |
Why?
|
| Optic Disk | 1 | 1994 | 3 | 0.030 |
Why?
|
| Congenital Hypothyroidism | 1 | 1994 | 2 | 0.030 |
Why?
|
| Maryland | 1 | 2013 | 8 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 72 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1994 | 51 | 0.030 |
Why?
|
| Myotonin-Protein Kinase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cell Membrane | 2 | 1984 | 82 | 0.030 |
Why?
|
| Mitochondrial Membranes | 1 | 2013 | 1 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 7 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2013 | 8 | 0.030 |
Why?
|
| MEF2 Transcription Factors | 1 | 2013 | 2 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 117 | 0.030 |
Why?
|
| Fecal Incontinence | 1 | 2012 | 2 | 0.030 |
Why?
|
| Health Policy | 1 | 2013 | 35 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 19 | 0.030 |
Why?
|
| Movement | 1 | 2013 | 110 | 0.030 |
Why?
|
| Dystonia | 1 | 2012 | 11 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2012 | 18 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 1994 | 69 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2012 | 2 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2012 | 3 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2012 | 6 | 0.020 |
Why?
|
| Glycosylation | 1 | 2012 | 18 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 30 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 34 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2005 | 10 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 55 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 87 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2012 | 23 | 0.020 |
Why?
|
| Gene Expression | 2 | 2008 | 196 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 1992 | 6 | 0.020 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 89 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 348 | 0.020 |
Why?
|
| Depression | 1 | 2015 | 390 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2011 | 3 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 7 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 18 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 281 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 40 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 197 | 0.020 |
Why?
|
| Arrhythmia, Sinus | 1 | 2011 | 2 | 0.020 |
Why?
|
| Respiratory Rate | 1 | 2011 | 3 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 18 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 95 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 41 | 0.020 |
Why?
|
| Monitoring, Ambulatory | 1 | 2011 | 17 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2011 | 2 | 0.020 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2011 | 2 | 0.020 |
Why?
|
| Weight Gain | 1 | 2011 | 56 | 0.020 |
Why?
|
| Embryo, Nonmammalian | 1 | 2011 | 7 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 27 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 18 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 43 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2010 | 1 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 62 | 0.020 |
Why?
|
| Electron Transport | 1 | 2010 | 3 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 21 | 0.020 |
Why?
|
| Tracheotomy | 1 | 2010 | 3 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2010 | 8 | 0.020 |
Why?
|
| Transfection | 3 | 1996 | 115 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 57 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2010 | 15 | 0.020 |
Why?
|
| Fathers | 1 | 2010 | 21 | 0.020 |
Why?
|
| Lamins | 1 | 2009 | 1 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2010 | 118 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2009 | 25 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2009 | 47 | 0.020 |
Why?
|
| Polysomnography | 1 | 2009 | 71 | 0.020 |
Why?
|
| Rotarod Performance Test | 1 | 2008 | 8 | 0.020 |
Why?
|
| Reversal Learning | 1 | 2008 | 1 | 0.020 |
Why?
|
| Canada | 1 | 2008 | 42 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2008 | 11 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 55 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 121 | 0.020 |
Why?
|
| Hypoxia | 1 | 2008 | 27 | 0.020 |
Why?
|
| 2-Chloroadenosine | 1 | 1988 | 1 | 0.020 |
Why?
|
| Calcimycin | 1 | 1988 | 3 | 0.020 |
Why?
|
| Adenosine | 1 | 1988 | 6 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1988 | 12 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 334 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 10 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1988 | 52 | 0.020 |
Why?
|
| Immunoassay | 1 | 1988 | 35 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2007 | 2 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2007 | 1 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 56 | 0.020 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2007 | 4 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2007 | 1 | 0.020 |
Why?
|
| Baroreflex | 1 | 2007 | 1 | 0.020 |
Why?
|
| Catecholamines | 1 | 2007 | 6 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 26 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2007 | 29 | 0.020 |
Why?
|
| Focus Groups | 1 | 2007 | 81 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 21 | 0.020 |
Why?
|
| Chicago | 1 | 2010 | 858 | 0.020 |
Why?
|
| Carbidopa | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 14 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 15 | 0.020 |
Why?
|
| Levodopa | 1 | 2006 | 34 | 0.020 |
Why?
|
| Fingers | 1 | 2006 | 8 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 412 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2006 | 45 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 24 | 0.020 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2006 | 2 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2006 | 13 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 49 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2006 | 47 | 0.020 |
Why?
|
| Alkaloids | 1 | 1986 | 3 | 0.020 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1986 | 6 | 0.020 |
Why?
|
| Tunicamycin | 1 | 1986 | 2 | 0.020 |
Why?
|
| Glucosamine | 1 | 1986 | 4 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1986 | 37 | 0.020 |
Why?
|
| G(M2) Ganglioside | 1 | 1985 | 1 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 1985 | 2 | 0.020 |
Why?
|
| G(M1) Ganglioside | 1 | 1985 | 2 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 1985 | 4 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1986 | 46 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2005 | 4 | 0.010 |
Why?
|
| Filamins | 1 | 2005 | 3 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 21 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 87 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2005 | 39 | 0.010 |
Why?
|
| CHO Cells | 2 | 1996 | 9 | 0.010 |
Why?
|
| Spiperone | 1 | 1984 | 1 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1984 | 3 | 0.010 |
Why?
|
| Apomorphine | 1 | 1984 | 3 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2004 | 11 | 0.010 |
Why?
|
| Autopsy | 1 | 2005 | 329 | 0.010 |
Why?
|
| Clergy | 1 | 2005 | 85 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 10 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 10 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 303 | 0.010 |
Why?
|
| Dementia | 1 | 2009 | 519 | 0.010 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2005 | 111 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 384 | 0.010 |
Why?
|
| Guanylyl Imidodiphosphate | 1 | 1983 | 1 | 0.010 |
Why?
|
| Ribonucleotides | 1 | 1983 | 1 | 0.010 |
Why?
|
| Clone Cells | 1 | 1983 | 11 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1983 | 18 | 0.010 |
Why?
|
| Enkephalins | 1 | 1983 | 1 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1983 | 3 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 24 | 0.010 |
Why?
|
| Cations | 1 | 1983 | 11 | 0.010 |
Why?
|
| Apolipoprotein E2 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cerebellar Cortex | 1 | 2002 | 7 | 0.010 |
Why?
|
| Apolipoprotein E3 | 1 | 2002 | 16 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1983 | 35 | 0.010 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 8 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2002 | 17 | 0.010 |
Why?
|
| Mental Recall | 1 | 2002 | 60 | 0.010 |
Why?
|
| Narcotics | 1 | 1983 | 34 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 234 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 254 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 141 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 177 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 115 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1998 | 3 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1998 | 19 | 0.010 |
Why?
|
| Phospholipase D | 1 | 1996 | 5 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1996 | 16 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1996 | 8 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 25 | 0.010 |
Why?
|
| Antibodies | 1 | 1996 | 43 | 0.010 |
Why?
|
| Neurofilament Proteins | 1 | 1996 | 17 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1996 | 43 | 0.010 |
Why?
|
| Methylation | 1 | 1994 | 8 | 0.010 |
Why?
|
| Hexosaminidase A | 1 | 1994 | 1 | 0.010 |
Why?
|
| Hexosaminidase B | 1 | 1994 | 1 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 6 | 0.010 |
Why?
|
| Serine | 1 | 1994 | 10 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1994 | 20 | 0.010 |
Why?
|
| Tyrosine | 1 | 1994 | 19 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 143 | 0.010 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1993 | 3 | 0.010 |
Why?
|
| Glioma | 1 | 1993 | 19 | 0.010 |
Why?
|
| Lysergic Acid | 1 | 1993 | 1 | 0.010 |
Why?
|
| Glucose | 1 | 1993 | 46 | 0.010 |
Why?
|
| Biological Transport | 1 | 1993 | 37 | 0.010 |
Why?
|
| Paroxetine | 1 | 1993 | 14 | 0.010 |
Why?
|
| Receptors, Opioid | 1 | 1986 | 1 | 0.000 |
Why?
|
| Swainsonine | 1 | 1986 | 1 | 0.000 |
Why?
|
| Receptors, Opioid, delta | 1 | 1986 | 1 | 0.000 |
Why?
|
| Receptors, sigma | 1 | 1986 | 1 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1986 | 89 | 0.000 |
Why?
|